Metastasis from Malignant Tumor of Cervix clinical trials at University of California Health

1 research study open to eligible people

NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
open to eligible people ages 18 years and up
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
at UCSF

Our lead scientists for Metastasis from Malignant Tumor of Cervix research studies include Jason Chan.

Last updated: January 13, 2025

NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy